EP3860604A1 - Soutien nutritionnel de processus naturels de cicatrisation de plaies - Google Patents

Soutien nutritionnel de processus naturels de cicatrisation de plaies

Info

Publication number
EP3860604A1
EP3860604A1 EP19790121.8A EP19790121A EP3860604A1 EP 3860604 A1 EP3860604 A1 EP 3860604A1 EP 19790121 A EP19790121 A EP 19790121A EP 3860604 A1 EP3860604 A1 EP 3860604A1
Authority
EP
European Patent Office
Prior art keywords
preparation
vitamin
per gram
base
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19790121.8A
Other languages
German (de)
English (en)
Inventor
Cathrin Lindenschmidt
Alexander Maassen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanafactur GmbH
Original Assignee
Sanafactur GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanafactur GmbH filed Critical Sanafactur GmbH
Publication of EP3860604A1 publication Critical patent/EP3860604A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention describes a preparation for oral administration, which is tailored to the special requirements of patients with wounds and supports the body's wound healing processes both locally and systemically.
  • wound dressings which, in particular in the case of wounds localized on the body surface, are intended to promote this healing process by creating an environment which is conducive to wound healing or to reduce side effects of the wound, such as unpleasant odors, and thus to improve the quality of life of the patients.
  • wound dressings A wide range of different wound dressings is available to the specialists working in wound care today in order to be able to take good care of the patients according to the peculiarities of the respective wound.
  • wound healing is not a purely local process at the wound site.
  • a prerequisite for successful wound healing is a suitable framework that affects the entire body. This includes, in particular with so-called "secondary" wound healing, the provision of the nutrients required for more or less extensive new tissue formation. Patients with larger wounds therefore have a significantly higher nutrient requirement than comparable healthy patients. Any lack of a micro or macronutrient becomes the limiting factor for new tissue formation and the desired wound closure.
  • WO 2014/022886 A1 describes a preparation which has particularly positive effects in patients with atopic and non-atopic eczema. These diseases are based on genetic and immunological causes and result in inflammatory reactions which cause malnutrition and to which the Preparation with its ingredients such as glycine, vitamin B6, taurine or magnesium tries to act. Even if inflammatory reactions can play a role in disorders in certain phases of wound healing, it is only a small part of the metabolic pathways involved in wound healing. The fact that the addition of zinc mentioned in this publication has a positive effect on wound healing is well known and described in this general document.
  • EP 2 196 099 A1 describes a preparation which primarily aims to optimize the immune processes of the patient. A mixture of maltodextrin, arginine, omega-3 fatty acids, collagen, vitamins and zinc is considered beneficial.
  • EP 0 960 572 A1 describes a preparation which contains arginine, vitamin C, vitamin E, flavonoids and other macro- and micronutrients and, in addition to improving wound healing, is said to also have improved effects on blood circulation and on the control of inflammation .
  • EP 1 633 377 B1 describes a preparation including macronutrients with an increased content of the amino acids leucine and / or glycine. This preparation aims to stimulate or compensate for inadequate prolidase activity, which plays a role in the synthesis of relevant molecules as building blocks for local tissue regeneration.
  • the preparation according to WO 2013/106570 A1 is a combination of beta-hydroxy-beta-methylglutamine (HMB), arginine and glutamine and possibly other macronutrients and is specially tailored to support the wound healing of wounds of patients with diabetic ulcers, some have reduced serum albumin levels and reduced blood flow to the extremities.
  • HMB beta-hydroxy-beta-methylglutamine
  • arginine arginine
  • glutamine possibly other macronutrients
  • the preparation starts with a very specific subgroup of patients with wounds and with them specifically on certain metabolic pathways.
  • the preparation according to WO 97/16079 A1 is aimed at the nutritional requirements of children up to 10 years of age, which - as stated in the publication - differ greatly from the requirements of adult patients.
  • the preparation corresponds to a complete diet tailored to children, a subclaim also describes a positive effect on wound healing by adding certain fatty acids and protein sources rich in cysteine.
  • the above-mentioned preparations as prior art therefore primarily act either systemically, for example on the immune system, or are intended to support certain aspects of micronutrient supply or local biochemical wound healing processes.
  • wound healing requires a body-wide synchronization of both local biochemical synthesis processes for tissue regeneration and systemic processes beyond the provision of nutrients.
  • the substances contained in the above-mentioned preparations are all components of common nutritional recommendations and their fundamentally positive effect on wound healing at one level or another has been adequately described.
  • the use according to the invention of the preparation according to claim 1 for oral intake aims to support local and systemic processes in addition to the provision of the micro- and macronutrients required for wound healing.
  • Basic preparation therefore serves a common mixture of vitamins and nutrients, which is based on the nutritional recommendations for healthy people.
  • the base preparation according to the invention used according to claim 1 contains the substances and amounts listed in Table 2 per gram of the base preparation.
  • Table 1 the recommended daily intake according to Commission Directive 2008/100 / EC of October 28, 2008 is shown in Table 1.
  • Some of the substances are used for basic care in order to avoid certain shortages of care that limit wound healing ("basic care").
  • the coverage of the recommendations from Table 1 per gram of the base preparation is increased by a factor of 1.2 to 5.8 for the substances of the actual active complex to achieve the surprising, particularly positive effect compared to the substances of the basic care.
  • One gram of the basic preparation therefore covers 30% to 35% of the respective recommendations according to Table 1, but 40% to 195% of the respective recommendation for the substances of the active complex from the basic supply.
  • Table 1 Daily recommended intake according to Commission Directive 2008/100 / EC of October 28, 2008
  • Table 2 Composition of the basic preparation, consisting of a basic supply and increased proportions of the active complex
  • the basic preparation can contain both the (pure) substances listed in Table 2 and their compounds, whereby only the weight fraction of the pure substance contained is taken into account for the determination of the amount per gram of basic preparation for the information in Table 2 for compounds.
  • the difference in weight between the amounts given in table 2, column 3, to one gram corresponds to the weight of the counterions, for example the minerals, the molecules which may also be associated with the pure substances, such as complexing agents, as well as other auxiliary substances which may be required and have no therapeutic effect.
  • this basic preparation can be designed particularly advantageously by adding further substances which are useful in combination with the basic preparation for wound healing.
  • the additional amounts added are given below in relation to the base preparation contained in the overall preparation, ie the amount which is additionally contained in the overall preparation per gram of the base preparation contained.
  • the preparation used it additionally contains 3 mg to 200 mg of typtophan (pure or measured as the weight of the tryptophan in its compounds) per gram of the base preparation contained.
  • the preparation used it additionally contains 0.1 g to 4 g arginine (pure or measured as the weight of the arginine its compounds) per gram of the base preparation contained.
  • the preparation used it additionally contains 0.1 g to 4 g of glutamine (pure or measured as the weight of the glutamine in its compounds) per gram of the base preparation contained.
  • the preparation used it additionally contains 3 g to 30 g of protein in the form of proteins, peptides, amino acids or a mixture thereof per gram of the base preparation in order to provide sufficient proteins for new tissue formation.
  • Wound healing is an ongoing process. However, nutrients are only supplied at mealtimes or when the preparation is taken, and therefore discontinuously.
  • This embodiment reduces the risk of reduced protein availability between meals occurring in patients with existing wounds due to their increased protein requirement, which leads to delays in the complex wound healing process and thereby increase the risk of complications such as infections.
  • the protein of the preparation used therefore consists of a mixture of a. protein sources slowly available to the body from the family of whey proteins (e.g.
  • hen's egg proteins whole egg or protein
  • vegetable proteins e.g. soy or pea proteins
  • protein absorption rate of less than 7 g / h
  • protein sources from the whey protein family (e.g. whey), partially pre-digested proteins (yeast or other protein hydrolyzates) or peptides or amino acids with a protein absorption rate of more than 7 g / h.
  • the proportion of slowly available protein sources is between 50 and 90% of the total protein content of the preparation used.
  • amino acids alanine, glycine and cysteine can be synthesized by the body, but supplementation has proven to be advantageous in combination with the preparation used here. Therefore, in a further preferred embodiment, in addition to the protein contained in the preparation used, in each case between 0.1 mg and 10 g of the amino acids mentioned per gram of the base preparation contained - individually or in any combination, as a pure amino acid or as a compound with a high proportion the amino acid. Peptides are mentioned here as an example. The amounts of the additionally added amino acids mentioned can be seen independently of one another. Enrichment of all three amino acids is particularly preferred.
  • the preparation used is for the prevention of wounds or wound healing complications prior to the formation of a wound or the prevention of recurrences and therefore does not require a separate addition of protein.
  • the preparation used contains between 0.1 and 3 g of sources of omega-3-rich fatty acids per gram of the base preparation contained.
  • sources of omega-3-rich fatty acids can include one or more substances from the family of vegetable oils (e.g.
  • linseed oil if it contains between 50 and 750 mg eicosapentaenoic acid (EPA) and between 50 and 750 mg docosahexaenoic acid (DHA) per gram of the basic preparation, used directly as a pure substance or as a component of the aforementioned fatty acid sources.
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • the preparation used contains between 0.5 and 5 g of one or more blood sugar regulating substances per gram of the base preparation contained.
  • these can be substances from the family of cyclodextrins, b-glucans or modified methyl celluloses (for example hydroxypropyl methyl cellulose, or HPMC for short).
  • Many older patients with larger wounds suffer from diabetes melitus. The normal control of blood sugar levels is disturbed in these patients. With all treatment options, these patients' blood sugar levels rise to a level after a meal, which can significantly disrupt or interrupt normal wound healing processes.
  • the addition described can delay the absorption of sugar via the intestine and, in diabetics, the blood sugar peaks which are harmful to wound healing after a meal can be reduced.
  • the mass fraction of the substances mentioned is between 5 and 20% of the total mass of the preparation for one serving.
  • the oral intake of the preparation used is offered in a directly ingestible form, for example in the form of a tablet or capsule or a combination thereof.
  • the preparation is completed before oral administration, for example by mixing with solid or liquid foods, and is thus taken.
  • any form of beverage is explicitly to be regarded as liquid food.
  • This configuration can for example in the form of tablets, capsules, granules or a combination thereof.
  • the preparation used is offered in the form of two separate components.
  • the first component essentially contains the aforementioned components that support the wound healing processes.
  • the second component is offered separately and is used to add more flavors to the finished preparation and thus quickly offer different flavors.
  • the use of the second component does not preclude the use of flavors in the first component.
  • the two components have a pronounced color contrast, which is intended to stimulate the appetite of the patient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'une préparation destinée au soutien nutritionnel des processus naturels de cicatrisation de plaies sur le plan local et systémique, par réception par voie orale de la préparation, laquelle contient, en tant que préparation de base par gramme, un mélange usuel de vitamines et de nutriments, qui est fondé sur les recommandations nutritionnelles en matière de santé (substances ci-dessous [a-f], voir la directive 2008/100/EG, voir le Journal officiel de l'Union européenne, L285, pages 9 à 12) : a. 330 à 385 μg de vitamine B1, b. 420 à 490 μg de vitamine B2, c. 4,8 à 5,6 mg de vitamine B3, d. 1,8 à 2,1 mg de vitamine B5, e. 420 à 490 μg de vitamine B6, f. 15 à 18 μg de vitamine H, et qui contient des quantités accrues par rapport aux recommandations des substances ci-dessous [g-k], par gramme de préparation de base : g. 80 à 390 μg de vitamine B9, h. 1,0 à 4,9 μg de vitamine B12, i. 32 à 156 mg de vitamine C, j. 150 à 731 mg de magnésium et k. 4 à 20 mg de zinc.
EP19790121.8A 2018-10-01 2019-09-26 Soutien nutritionnel de processus naturels de cicatrisation de plaies Withdrawn EP3860604A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102018124227.1A DE102018124227A1 (de) 2018-10-01 2018-10-01 Zubereitung zur Verbesserung körpereigener Wundheilung
PCT/DE2019/100850 WO2020069695A1 (fr) 2018-10-01 2019-09-26 Soutien nutritionnel de processus naturels de cicatrisation de plaies

Publications (1)

Publication Number Publication Date
EP3860604A1 true EP3860604A1 (fr) 2021-08-11

Family

ID=68290131

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19790121.8A Withdrawn EP3860604A1 (fr) 2018-10-01 2019-09-26 Soutien nutritionnel de processus naturels de cicatrisation de plaies

Country Status (6)

Country Link
US (1) US20210369772A1 (fr)
EP (1) EP3860604A1 (fr)
AU (1) AU2019352938A1 (fr)
CA (1) CA3114666A1 (fr)
DE (1) DE102018124227A1 (fr)
WO (1) WO2020069695A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026019379A1 (fr) * 2024-07-13 2026-01-22 Humanis Sağlik A.Ş. Composition pharmaceutique contenant de la vitamine b

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714472A (en) 1993-12-23 1998-02-03 Nestec Ltd. Enternal formulation designed for optimized nutrient absorption and wound healing
US5635199A (en) * 1995-10-27 1997-06-03 Nestec Ltd. Support of pediatric patients
US5733884A (en) 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
EP0960572A1 (fr) 1998-05-12 1999-12-01 N.V. Nutricia Composition nutritive pour le traitement des escarres ud décubitus
JP2007500208A (ja) 2003-05-22 2007-01-11 エヌ．ブイ．・ヌートリシア 慢性創傷の治療方法又は予防方法並びにそれに使用するためのグリシン及び／又はロイシンを含む完全栄養組成物
EP1543735B1 (fr) 2003-12-20 2015-10-07 Nestec S.A. Composition nutritionnelle de cicatrisation des plaies
US8466187B2 (en) * 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
IT1392084B1 (it) 2008-12-12 2012-02-09 Marzullo Composizione immuno-nutrizionale
US20120308525A1 (en) 2009-11-25 2012-12-06 Nestec S.A. Nutritional compositions including a high protein component and exogenous nucleotides
CN104302285A (zh) 2012-01-11 2015-01-21 雅培制药有限公司 用于治疗糖尿病性溃疡的β-羟基-β-甲基丁酸盐、精氨酸和谷氨酰胺的组合产品
WO2014022886A1 (fr) * 2012-08-08 2014-02-13 Fischer Karen Jane Procédé, utilisation et composition de complément alimentaire pour au moins traiter un trouble atopique ou non-atopique chez un patient
US10413528B2 (en) * 2014-10-20 2019-09-17 John H. Plumb Methods to inhibit infection during wound healing with topical compositions including amino acids
JP2018052890A (ja) * 2016-09-30 2018-04-05 ニュートリー株式会社 術後の創傷治癒過程における炎症期の創傷治癒を促進するための栄養組成物
EP3541205B1 (fr) * 2016-11-16 2024-05-22 Fresenius Kabi Deutschland GmbH Compositions liquides complètes sur le plan nutritionnel à utiliser dans le traitement de la malnutrition associée à la maladie pulmonaire obstructive chronique, aux maladies ou troubles neurologiques et/ou aux plaies, comprenant un hydrolysat de collagène

Also Published As

Publication number Publication date
AU2019352938A1 (en) 2021-05-06
CA3114666A1 (fr) 2020-04-09
DE102018124227A1 (de) 2020-04-02
US20210369772A1 (en) 2021-12-02
WO2020069695A1 (fr) 2020-04-09

Similar Documents

Publication Publication Date Title
DE69624768T2 (de) Ernährungszusammensetzung
EP1041896B1 (fr) Melange de corps gras
DE60119919T2 (de) Freie aminosäure enthaltende zusammensetzung
DE3138088C2 (fr)
DE10057290B4 (de) Enteral zu verabreichendes Supplement zur parenteralen Ernährung oder partiellen enteralen/oralen Ernährung bei kritisch Kranken, chronisch Kranken und Mangelernährten
EP1978949B1 (fr) Préparation combinée destinée à améliorer la qualité du sperme
EP0756827B1 (fr) Préparation pour l'alimentation
DE69814834T2 (de) Ernährungszusammensetzung zur verbesserung der zellenenergie
EP1633207A1 (fr) Aliments dietetiques pour une alimentation visant a controler voire reduire le poids
CH646056A5 (de) Lipide senkendes mittel.
DE69633818T2 (de) Verwendung eines mittels zur zur vorbeugung oder behandlung von durch anomalitäten des knorpelgewebes verursachten erkrankungen
EP0928565B1 (fr) Liquide potable
DE2352797A1 (de) Ernaehrungszusatz
WO2008138821A1 (fr) Composition à base de matière grasse lactique et de protéine lactique (de préférence, estérifiée par l'acide palmitique) destinée à l'amélioration de l'absorption du calcium
WO2013006982A1 (fr) Système diététique multi-composants
WO2020069695A1 (fr) Soutien nutritionnel de processus naturels de cicatrisation de plaies
DE60128322T2 (de) Verfahren zur Extraktion von Flavon-Gemischen, die dabei erhaltenen Gemische sowie deren Verwendung in Dermokosmetika, Ernährung und Pharmazeutika
WO2016009021A1 (fr) Forme galénique contenant des composants fongiques
WO2024023311A1 (fr) Comprimé soluble notamment destiné à être utilisé en tant que complément alimentaire
DE202013002498U1 (de) Futtermittelzusatz für Nutz- und Haustiere
EP1916913A2 (fr) Composition a base de proteines pour traiter des besoins supplementaires en proteines, inherents a la physiologie et non apparents sur le plan clinique
EP1687014A1 (fr) Utilisation de dreche de distillerie fermentee pour prevenir et/ou traiter des taux augmentes de glycemie
DE102018125223A1 (de) Ketogene Proteinzubereitung
WO2024208506A1 (fr) Combinaison de principes actifs oraux contenant de la l-arginine, de la l-citrulline, du sélénite et du bore soluble dans l'eau
DE20212933U1 (de) Vitamin- und Spurenelemente-Mischung für Nierenkranke

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210319

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240613

17Q First examination report despatched

Effective date: 20240625

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20241026